← Back to Search

Behavioural Intervention

PAC Provision for Heart Failure (PATHFINDER Trial)

N/A
Recruiting
Led By David Lanfear, MD
Research Sponsored by Henry Ford Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Currently hospitalized with plan to be discharged to home
Primary discharge diagnosis heart failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 and 90 days post-enrollment

Summary

This trial, called PATHFINDER, is part of a larger project called ACHIEVE GREATER. The goal of the project is to reduce health disparities and inequality between Black and White individuals in

Who is the study for?
This trial is for heart failure patients currently hospitalized and soon to be discharged home, with specific blood test results indicating heart failure severity. They must be able to participate fully in the study without long travel plans.
What is being tested?
The ACHIEVE PATHFINDER trial tests if portable air cleaners (PAC) given at hospital discharge can help manage heart failure. Patients are randomly assigned to receive a PAC or no intervention; some PACs have filters.
What are the potential side effects?
Since this trial involves non-invasive interventions like portable air cleaners, there are minimal expected side effects compared to drug treatments. Any potential discomfort would likely come from inconvenience or noise.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am in the hospital now but will be going home soon.
Select...
My main diagnosis when discharged was heart failure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 and 90 days post-enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 and 90 days post-enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The impact of PAC use for 90 days after hospital discharge for HF compared to sham on NTproBNP level.
Secondary study objectives
The effect of PAC use on clinical events (death) in the active PAC group versus sham group
The effect of PAC use on clinical events (hospitalization) in the active PAC group versus sham group
The effect of PAC use on home PM2.5 levels in active PAC group versus sham group
Other study objectives
Impact of PAC on hsCRP
Impact of PAC on hsTroponin
Impact of PAC use on health status

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: PAC Intervention ArmActive Control1 Intervention
Participants randomized to the interventional arm will be given 2 PAC units with HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters.
Group II: Control non-interventional ArmPlacebo Group1 Intervention
Participants randomized to the non-interventional arm will be given 2 PAC units without HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters.

Find a Location

Who is running the clinical trial?

Henry Ford Health SystemLead Sponsor
311 Previous Clinical Trials
2,175,993 Total Patients Enrolled
9 Trials studying Heart Failure
1,005 Patients Enrolled for Heart Failure
Wayne State UniversityOTHER
315 Previous Clinical Trials
110,537 Total Patients Enrolled
10 Trials studying Heart Failure
4,888 Patients Enrolled for Heart Failure
David Lanfear, MDPrincipal InvestigatorHenry Ford Health
1 Previous Clinical Trials
105 Total Patients Enrolled
1 Trials studying Heart Failure
105 Patients Enrolled for Heart Failure
~251 spots leftby Dec 2026